· Revenue growth of 8.0%, driven by the excellent performance of Theranostics, up 15.5%, and the substantial expansion in activity in the United States, up 34.0% · Substantial improvement of 44.5% in the net result…
Excellent performance for Theranostics sales, with growth of 15.5% Substantial expansion in activity in the United States, materialized by growth of 34.0% Solid performance for sales in France, driven by IVD activity Cash position at…
Croissy-Beaubourg, January 14, 2021, 5:45 pm CET – THERADIAG (ISIN: FR0004197747, Ticker: ALTER), a company specializing in in vitro diagnostics and theranostics, today announces that it has signed an partnership contract with ORGENTEC, a German…